Cryo-Cell International (STU:ZCY) ROE %: Negative Equity% (As of Feb. 2026)


STU:ZCY Cryo-Cell International Inc STU:ZCY
58 GF Score
Price €2.78
GF Value €4.98
Valuation Possible Value Trap
! 5 Warning Signs
View Full Analysis

What is Cryo-Cell International ROE %?

Cryo-Cell International STU:ZCY +17.80% 58 ROE % is Negative Equity% as of Feb. 2026. GuruFocus rates STU:ZCY with a GF Score™ of 58/100 and a GF Value™ of €4.98 (Possible Value Trap). The stock has 5 warning signs investors should review. Among 626 Healthcare Providers & Services companies, Cryo-Cell International ranks worse than 159744.25% on this metric.

ROE % is calculated as Net Income divided by its average Total Stockholders Equity over a certain period of time. Cryo-Cell International's annualized net income for the quarter that ended in Feb. 2026 was €0.16 Mil. Cryo-Cell International's average Total Stockholders Equity over the quarter that ended in Feb. 2026 was €-15.83 Mil. Therefore, Cryo-Cell International's annualized ROE % for the quarter that ended in Feb. 2026 was Negative Equity%.

The historical rank and industry rank for Cryo-Cell International's ROE % or its related term are showing as below:

During the past 13 years, Cryo-Cell International's highest ROE % was 274.39%. The lowest was 0.00%. And the median was 241.37%.

STU:ZCY's ROE % is not ranked *
in the Healthcare Providers & Services industry.
Industry Median: 5.805
* Ranked among companies with meaningful ROE % only.

Cryo-Cell International  (STU:ZCY) ROE % Explanation

ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.

The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:

ROE %(Q: Feb. 2026 )
=Net Income/Total Stockholders Equity
=0.16/-15.83
=(Net Income / Revenue )*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(0.16 / 26)*(26 / 52.4525)*(52.4525 / -15.83)
=Net Margin %*Asset Turnover*Equity Multiplier
=0.62 %*0.4957*N/A
=ROA %*Equity Multiplier
=0.31 %*N/A
=Negative Equity %

With this breakdown, it is clear that if a company grows its Net Profit Margin, its Asset Turnover, or its Leverage, it can grow its ROE %.

The factors that affect a company's ROE % can also be illustrated with the five-step DuPont Analysis:

ROE %(Q: Feb. 2026 )
=Net Income/Total Stockholders Equity
=0.16/-15.83
=(Net Income / Pre-Tax Income) * (Pre-Tax Income / Operating Income) * (Operating Income / Revenue) * (Revenue / Total Assets) * (Total Assets / Total Stockholders Equity)
= (0.16 / 0.236) * (0.236 / 2.588) * (2.588 / 26) * (26 / 52.4525) * (52.4525 / -15.83)
= Tax Burden * Interest Burden * Operating Margin % * Asset Turnover * Equity Multiplier
= 0.678 * 0.0912 * 9.95 % * 0.4957 * N/A
=Negative Equity %

Note: The net income data used here is four times the quarterly (Feb. 2026) net income data. The Revenue data used here is four times the quarterly (Feb. 2026) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Net Income is used.

Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.


Cryo-Cell International ROE % Related Terms


Cryo-Cell International ROE % Historical Data

* Premium members only.

The historical data trend for Cryo-Cell International's ROE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cryo-Cell International ROE % Chart

Cryo-Cell International Annual Data
Trend Nov16 Nov17 Nov18 Nov19 Nov20 Nov21 Nov22 Nov23 Nov24 Nov25
ROE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 259.01 250.51 0.00 Negative Equity 0.00

Cryo-Cell International Quarterly Data
May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24 May24 Aug24 Nov24 Feb25 May25 Aug25 Nov25 Feb26
ROE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Negative Equity Negative Equity Negative Equity 0.00 Negative Equity

STU:ZCY vs CCM, CDIX, EHSI: ROE % Comparison

For the Medical Care Facilities subindustry, Cryo-Cell International's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cryo-Cell International ROE % vs Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, Cryo-Cell International's ROE % distribution charts can be found below:

* The bar in red indicates where Cryo-Cell International's ROE % falls into.


STU:ZCY
58GF Score
Cryo-Cell International Inc STU:ZCY
ROE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Cryo-Cell International ROE % Calculation

Cryo-Cell International's annualized ROE % for the fiscal year that ended in Nov. 2025 is calculated as

ROE %=Net Income (A: Nov. 2025 )/( (Total Stockholders Equity (A: Nov. 2024 )+Total Stockholders Equity (A: Nov. 2025 ))/ count )
=-2.101/( (-12.449+-16.094)/ 2 )
=-2.101/-14.2715
=N/A %

Cryo-Cell International's annualized ROE % for the quarter that ended in Feb. 2026 is calculated as

ROE %=Net Income (Q: Feb. 2026 )/( (Total Stockholders Equity (Q: Nov. 2025 )+Total Stockholders Equity (Q: Feb. 2026 ))/ count )
=0.16/( (-16.094+-15.566)/ 2 )
=0.16/-15.83
=Negative Equity %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data, the net income data used here is four times the quarterly (Feb. 2026) net income data. ROE % is displayed in the 30-year financial page.

* Note that if the average Total Stockholders Equity is zero or negative, then ROE % would be considered meaningless and hence not be calculated.

Frequently Asked Questions Learn more about ROE % →
What does a ROE % of Negative Equity% mean?
Cryo-Cell International (STU:ZCY) has a ROE % of Negative Equity% as of Feb. 2026. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on Cryo-Cell International and its competitors. According to the industry distribution chart, Cryo-Cell International ranks #999999 out of 626 companies in the Healthcare Providers & Services industry.
Is Cryo-Cell International's ROE % too high?
Cryo-Cell International's current ROE % is Negative Equity%. Based on the distribution chart, Cryo-Cell International ranks #999999 out of 626 companies in the Healthcare Providers & Services industry, which is in the bottom quartile relative to peers. Overall, Cryo-Cell International has a GF Score™ of 58/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Cryo-Cell International's ROE % compare to CCM and CDIX?
According to the Healthcare Providers & Services industry distribution chart, Cryo-Cell International ranks #999999 out of 626 companies for ROE %. This places Cryo-Cell International in the lower half of its industry. The industry median ROE % is 5.81. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % for a Healthcare Providers & Services company?
The median ROE % among Healthcare Providers & Services companies is 5.81, based on 626 companies in the industry. Companies in the top quartile (top 25%) have a ROE % significantly above this median, while those in the bottom quartile fall well below. However, ROE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % mean?
A high ROE % can signal that a stock is expensive relative to its fundamentals. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on Cryo-Cell International and its competitors. For the Healthcare Providers & Services industry, the median ROE % is 5.81 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cryo-Cell International's current ROE % is Negative Equity%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cryo-Cell International stock overvalued right now?
Based on GuruFocus' analysis, Cryo-Cell International (STU:ZCY) is currently considered Possible Value Trap. The stock's GF Value™ is €4.98, compared to a current price of €2.78 — trading 44.2% below its estimated fair value. The current ROE % is Negative Equity%. Cryo-Cell International's overall GF Score™ is 58/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % calculated?
ROE % is calculated from a company's financial statements. For Cryo-Cell International (STU:ZCY), the current ROE % is Negative Equity% as of Feb. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Cryo-Cell International (STU:ZCY) Overvalued in 2026?

Based on GuruFocus' analysis, Cryo-Cell International stock appears to be undervalued. The current stock price of €2.78 is trading 44.2% below its estimated GF Value™ of €4.98. GuruFocus considers Cryo-Cell International to be Possible Value Trap.

Key valuation signals for STU:ZCY:

  • ROE %: Negative Equity%
  • GF Value™: €4.98 vs. price of €2.78 (44.2% below fair value)
  • GF Score™: 58/100 with 5 warning signs

No single metric tells the full story. See the STU:ZCY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Cryo-Cell International Business Description

Other Exchanges CCEL:USAZCY:Germany
Address 700 Brooker Creek Boulevard, Suite 1800, Oldsmar, FL, USA, 34677
Cryo-Cell International Inc is engaged in cellular processing and cryogenic storage. The company is organized into three reportable segments namely cellular processing and cryogenic storage, with a focus on the collection and preservation of umbilical cord blood and tissue stem cells for family use and the manufacturing of PrepaCyte CB units segment, which is a processing technology used to process umbilical cord blood stem cells. The cellular processing and cryogenic storage of umbilical cord blood stem cells for public use. The company generates maximum revenue from Cellular processing and Cryogenic storage and it derives revenue from processing and testing fees and Storage segment.
58GF Score

Get the complete analysis for STU:ZCY

ROE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€2.78
Price
€4.98
GF Value